A sthma is a chronic inflammatory process characterized by lung and airway inflammation accompanied by the infiltration of lymphocytes, basophils, mast cells, macrophages, and eosinophils (1, 2) . Eosinophilia is a hallmark feature of asthma, and it is well recognized that eosinophil migration is dependent on the eotaxin chemokines (3, 4) and the critical eosinophilopoietic and activating cytokine: IL-5 (4, 5) . Eosinophils elicit key effector functions in asthma pathogenesis by directing dendritic cell activation, promoting Ag presentation, activating mast cells, and releasing pleotropic cytokines (See Ref. 5 for review). Accordingly, eosinophils are now being pharmacologically targeted by a variety of new drugs (6, 7) , such as anti-IL-5 therapeutics (8, 9) . Molecular characterization of the eosinophil transcriptome by genome-wide array offers a potentially promising approach to comprehensively screen for molecules associated with eosinophil activation during allergic inflammation.
To molecularly characterize eosinophil activation in allergic lung inflammation, we performed a genome-wide mRNA microarray analysis of FACS-purified murine eosinophils from allergen (OVA-OVA)-or control (saline)-exposed lung samples. Transcriptome analysis revealed a pronounced differential expression of 82 genes in eosinophils obtained from allergen-exposed compared with control mice. Although multiple candidate genes could serve as eosinophil activation markers, carbonic anhydrase 4 (Car4) expression on activated eosinophils was both pronounced and unexpected. CAR4 belongs to a family of Zn 2+ -containing metalloenzymes that has numerous members (CAR1 to CAR15, sharing minimal homology) that interconvert HCO 3 2 and CO 2 (HCO 3 2 + H + → H 2 O + CO 2 ; for a recent review, see Ref. 10 by Waheed and Sly). CARs maintain acid-base balance in multiple tissue compartments so that harmful metabolic by-products can be rapidly removed, critical anions readily reabsorbed, and specific pH optimally maintained. CAR4 is expressed on CNS neurons, renal tubule epithelium, pulmonary capillary endothelium, and intestinal epithelium for metabolic acidosis buffering, HCO 3 2 reabsorption, lung CO 2 excretion, and anion exchanges, respectively (11) (12) (13) bone marrow identified differential expression of 37 transcripts in the asthmatic lung that was enriched in alterations in epithelial differentiation and keratinization processes. Collectively, we have determined that CAR4 is specifically upregulated in allergen-elicited pulmonary eosinophils, dependent on IL-5, and likely indirectly involved in a series of epithelial responses during allergic inflammation.
Materials and Methods

Mice Car4
2/2 mice on C57BL/6J background were obtained from The Jackson Laboratory (Bar Harbor, ME) from a recovery of cryopreserved embryos. Owing to the known breeding deficiency of Car4 2/2 homozygous mice (11), heterozygous matings were used in all experiments. In some initial validation experiments, BALB/c mice were subjected to CAR4 FACS staining, with no eosinophil CAR4 expression difference found between the two strains. All mice used in this study were housed in specific pathogen-free conditions at Cincinnati Children's Hospital Medical Center under Institutional Animal Care and Use Committee-approved protocols. All mice were housed in a room with an ambient temperature of 22˚C and a 12-h light cycle.
Genome-wide microarray analysis on sorted eosinophils and quantitative PCR validation
Tissue eosinophils were isolated from the perfused lung, as previously described (14) . In brief, eosinophils were sorted as DAPI
2 side scatter high (SSC high ) cells from 10 animals using the FACSAria (BD Biosciences). Total RNA from sorted eosinophils (purity, 95-99%) was extracted by a standard TRIzol (Life Technologies) RNA isolation and subsequently with an RNeasy Mini Kit (QIAGEN). RNA integrity was validated by the Agilent 2100 Bioanalyzer (Agilent Technologies). Eosinophil mRNA was amplified and labeled with the WT-Ovation Pico RNA Amplification System (NuGen) and subjected to the GeneChip Mouse Gene ST 1.0 Array chip (Affymetrix), which covers the whole mouse genome with 28,853 probe sets. The expression data were analyzed by the software of Genespring GX 11 (Agilent Technologies). Differential expression between activated lung eosinophils and saline controls was identified by upper 80th percentile expression, .2.0-fold change, and p , 0.05 with a false discovery rate (FDR) correction. For the lung tissue microarray following bone marrow transplantation, Affymetrix Mouse Gene ST 2.0 Array chips and a filter of .1.414-fold change and a Westfall-Young-corrected p , 0.01 were used. For real-time PCR confirmation, the same mRNA sample used for microarray analysis was reverse transcribed with the iScript cDNA Synthesis Kit (170-8891; Bio-Rad, Hercules, CA), and real-time PCR was performed with the iQ5 Real-Time PCR Detection System (Bio-Rad) using a pair of primers spanning exons 1 and 2 of the Car4 transcript (forward: 59-CATG-CAGCTCCTTCTTGCTCT-39; reverse: 59-TTTGAATCTCATAGCACCA-GCC-39), resulting in an 83-bp amplicon.
Flow cytometry analysis of eosinophil surface expression and signaling
Polychromatic flow cytometry compensation was preset in pilot studies for up to five channels on a FACSCanto II flow cytometer (BD Biosciences). Abs/dyes used in this study were purchased from BioLegend (CD11c-Pacific Blue N418, human Siglec 8 7C9, human CD11b ICRF44, human CD45 2D1), Invitrogen (LIVE/DEAD Violet dye), BD Biosciences (CD45-FITC 30-F11, Siglec F-PE E50-2440, CD11b-PECy7 M1/70, Gr-1 PerCP/ Cy5.5 RB6-8C5), and R&D Systems (msCAR4, AF2414). Staining was performed on ice for 30 min in staining buffer (0.5% BSA, 0.01% NaN 3 in 13 HBSS) with manufacturer-suggested titers. A secondary staining with the anti-goat AF488 was used for all CAR4 staining. Stained cells were resuspended and subjected to analysis with the BD FACSCanto II flow cytometer. In some experiments, stained cells were fixed before being subjected to FACS analysis in a controlled fashion. Raw flow cytometry data were analyzed by FlowJo software (TreeStar). For phosphor-FACS, eotaxin-1 (25 ng/ml) stimulation (2 min) was used for p44/42 MAPK activation assessment. Cells were immediately fixed by 2% formaldehyde at 37˚C for 10 min, followed by ice-cold methanol permeabilization for 30 min. Specific Thr 
CAR4 immunohistochemistry
A consistent lobe (lower right) of mouse lung tissue was fixed in 10% formalin under negative pressure for 6 h before regular paraffin embedding and sectioning procedures. After citric buffer Ag retrieval, the 5-mm sections were incubated with either anti-CAR4 polyclonal Ab (AF2414; R&D) or IgG control (AB-108-C; R&D) in 1% rabbit serum overnight at 4˚C, followed by incubation with biotinylated rabbit anti-goat secondary Ab for 1 h at room temperature. The slides were developed by a VEC-TASTAIN Elite ABC Kit (Vector Laboratories), following the standard manufacturer's protocol, and counterstained by hematoxylin.
Bone marrow-derived eosinophils
Whole bone marrow was cultured using a modification of previously described methods (15) . During the 14-d culture, the culture media were supplemented with FLT3 and stem cell factor at 100 ng/ml (PeproTech) for the first 4 d and IL-5 at 10 ng/ml (PeproTech) for the following 10 d. Results from H&E staining and FACS analysis indicated that the purity of eosinophils was .90% at day 14.
Experimental asthma induction
For the OVA model, mice were sensitized with 100 mg OVA/Alum twice, 14 d apart. For OVA intranasal challenge, OVA (100 mg in 50 mL saline) was administered for 3 consecutive days. Mice were sacrificed 48 h after the third OVA challenge for eosinophilia assessment. For the Aspergillus model, 100 mg Aspergillus fumigatus (GREER, Lenoir, NC) was dissolved in sterile saline and administered intranasally every other day into wild-type or IL-5-transgenic mice (BALB/c or C57BL6); a total of five challenges were given unless otherwise noted in the results. For the CC10-IL-13 transgenic model, IL-13 expression is driven by the lung epithelium promoter CC10 under the control of doxycycline (16) , and the asthma model was established after the mice were treated with doxycycline for 4 wk. 
Bone marrow transfer experiments
Lactate-induced acidification
Car4
+/+ and Car4 2/2 bone marrow-derived eosinophils were loaded with 5 mM pH-sensitive dye SNARF-1AM and then incubated with 15 mM lactate for 20 min. Intracellular pH (pHi) was determined by flow cytometry, comparing with eosinophils whose pHi was clamped with nigericin, as previously described (17) .
Statistical analysis
Statistical significance was analyzed using a two-tailed Student t test in all instances, unless otherwise noted. Data are graphed as mean 6 SEM. A p , 0.05 was deemed significant in experiments not involving a microarray, whose criteria are specifically mentioned in Materials and Methods and in Results.
Results
Eosinophil RNA microarray identifies a unique transcriptome with Car4 as a lead transcript After lung perfusion and collagenase digestion, lung tissue eosinophils were FACS sorted for
2 and SSC high events, from salinechallenged lung (Fig. 1A , upper panel) and OVA-challenged lung (Fig. 1A , lower panel). Eosinophil sorting purity (.95-99%) in saline and OVA samples was confirmed by back-running the sorted samples with an identical gating strategy (Fig. 1A) . Microarray analysis of these isolated cells led to the identification of a total of 82 genes that were differentially expressed, 78 upregulated and 4 downregulated, in eosinophils from OVA-challenged versus saline-challenged lungs (Fig. 1B , Supplemental Table I ). Among the most induced genes, Car4 mRNA was robustly upregulated by 36-fold (p , 0.0001, FDR-corrected p = 0.01) in eosinophils following OVA challenge (Fig. 1C) . We next confirmed the Car4 mRNA upregulation by quantitative PCR from the same sorted RNA sample, verifying a dramatic 165-fold increase after normalizing to Gapdh (p , 0.0001, Fig. 1D ). To assess the potential involvement of other CARs, we also collectively analyzed the differential expression level of all 15 CAR family member transcripts embedded on the array and found that eosinophil Car4 upregulation was unique among all of the CAR members screened (Fig. 1E) .
Lung eosinophil CAR4 surface expression is driven by Th2 inflammation
We aimed to validate CAR4 expression at the protein level on both BALF and lung tissue eosinophils following allergen (A. fumigatus) challenge (18) Fig. 2A) , resulting in .99% purity from BALF (Figs. 1A, 2F ). We therefore used 
2 SSC high with a purity . 95-99% confirmed by sample back-run (saline and OVA, before and after FACS sorting graphs shown). (B) Eosinophil mRNA was subjected to genome-wide mRNA microarray (Affymetrix mouse ST 1.0 chip), resulting in 78 upregulated and 4 downregulated genes following activation (upper 80th percentile expression, fold change .2.0, FDR-corrected p , 0.05). On the basis of these significant genes, a heat-map was established, double-clustered on entity (gene, y-axis) and condition (treatment, x-axis), with yellow indicating high expression and blue indicating low expression (Supplemental Table I a similar gating strategy to study eosinophil populations by FACS throughout this study. Gated on BALF eosinophils, CAR4 staining controlled by nonspecific IgG staining revealed robust CAR4 surface staining only on Car4 +/+ BALF eosinophils, but not on Car4 2/2 BALF eosinophils and not on blood eosinophils from the same animal of either genotype (Fig. 2B ). We identified a comparable CAR4 expression pattern in the OVA-challenging model that was originally used in the sorting-based microarray (Supplemental Fig. 1A ). We also assessed CAR4 surface expression on major leukocytes in the lung, BALF, and blood. Of note, unlike lung eosinophils, which expressed surface CAR4 only following allergen challenges, lung macrophages (under homeostasis or allergen challenge), but not lymphocytes and neutrophils, also expressed CAR4 on their surface independent of allergic inflammation (Supplemental Fig. 2A ).
We next examined CAR4 surface expression on lung tissue eosinophils from wild-type and Il5 transgenic mice and identified a similar heterogeneous expression pattern, with the latter exhibiting more robust CAR4 expression (Fig. 2C) , suggesting a role for IL-5 in CAR4 induction. As IL-13 is sufficient to elicit extensive lung eosinophilia (19), we used the CC10-IL-13 transgenic system (16) to assess the role of IL-13 in eosinophil CAR4 induction. Of note, IL-13 overexpression failed to induce eosinophil CAR4 expression (Fig. 2D) despite the presence of extensive eosinophilic lung inflammation.
Notably, heterogeneous expression of CAR4 was consistently observed after five allergen challenges, typically resulting in a double-peak histogram, with ∼50% of the eosinophils remaining CAR4 negative (CAR4 2 ). FACS imaging micrographs identified surface labeling of CAR4 and the coexistence of CAR4 + and CAR4 2 eosinophils in the BALF from mice with allergic inflammation (Fig. 2E) . were also used to prepare a cytospin slide for morphological evaluation under 3400 microscopy (25-mm bar superimposed). ***p , 0.001, two-tailed Student t test, mean 6 SEM.
spite comparable morphology (Fig. 2F) . In addition, heterogeneous CAR4 expression on eosinophils did not correlate with eosinophil physical parameters (forward and side scatter) or a panel of known eosinophil/granulocyte surface markers related to key functions (CCR3, Siglec-F, CD11b, CD11c, Gr-1, a4, aE, b1, b2 and b7 integrin, and L-selectin/CD62L, IL-5R/CD125, CD69, CD86, CD25, and intracellular IL-4) (Supplemental Fig.  1B ). In addition, an unaltered eotaxin-CCR3 signaling strength was found on the basis of p44/42 MAPK activation capacity of CAR4 + and CAR4 2 eosinophils (Supplemental Fig. 1C , Car4
+/+ sample used). We also examined CAR4 distribution in the normal and allergic lung by immunohistochemistry (IHC). In the OVA asthma model, whereas CAR4 was positive in the alveolar area regardless of treatment, CAR4-positive infiltrating inflammatory cells were found in OVA lung only in the anatomical regions traversing blood vessel and airway (the asthmatic pathogenic zone), an area clearly CAR4 negative in the saline control (Fig. 3A, 3200) . At higher power magnification (3400), in a different asthma model (induced by A. fumigatus Ag), CAR4-positive events were found only in the CAR4 +/+ lung stained with CAR4, not in the CAR4 2/2 lung, and not in the IgG control staining in both cases (Fig. 3B) . A highpower micrograph focusing on the alveolar region revealed CAR4 expression on lung macrophages and eosinophils (Fig. 3C ).
IL-5 is necessary and sufficient for eosinophil CAR4 surface induction
The enhanced CAR4 expression in eosinophils from IL-5 transgenic mice led us to hypothesize that IL-5 is a key driver of CAR4 induction during allergic airway inflammation. To test this hypothesis, the ability of IL-5 to modulate CAR4 expression during eosinophil development was assessed (15) . Indeed, CAR4 on de- (Fig. 4C) , whereas eosinophils from Il5 +/+ mice were mostly CAR4 + . Of note, CAR4 demonstrated more homogeneous staining under these experimental conditions, likely the result of administering seven allergen challenges. To further determine whether IL-5 was necessary and sufficient, we exposed BALF cells from Il5 2/2 allergen-challenged mice to exogenous IL-5 for 72 h (20 ng/ml) and compared the eosinophil CAR4 expression before and after IL-5 exposure. IL-5 treatment indeed induced CAR4 expression (Fig. 4D) . Compared with Car4 +/+ eosinophils, Car4 2/2 bone marrow-derived eosinophils did not exhibit a difference in differentiation in terms of specific surface marker expression, yield, or morphology (Supplemental Fig. 1D and data not shown).
Biochemical assessment of putative Car4 functions on eosinophils
Considering the reported functions of CAR4 (11, 12, 20) , we examined the cellular buffering capacity by bone marrow-derived eosinophils. Cellular pH buffering capacity was readily observed for eosinophils, with Car4 +/+ and Car4 2/2 eosinophils having similar activity (Fig. 5A) . A well-established function of membranebound carbonic anhydrases is to enable lactate transport into cells by buffering extracellular pH following lactate-H + cotransport (21, 22) . Because readout of this process is intracellular acidification following lactate treatment, the pHi in cultured eosinophils was monitored by a pH-sensitive dye following addition of lactate. Although the intracellular acidification was readily observed, no difference in intracellular acidification was found between CAR4 +/+ and CAR4 2/2 eosinophils (Fig. 5B) .
A novel epithelium-modulating function of eosinophil CAR4
We next investigated whether CAR4 expression on eosinophils could affect eosinophil migration and levels in the allergic airway. For this purpose, we allergen challenged irradiated CD45.1 bone marrow recipient mice that have been adoptively transferred with either Car4 +/+ or Car4 2/2 bone marrow from CD45.2 donor mice.
CD45.2 donor engraftment (CD11b + ) was .99%, as assessed by the presence of CD45.2 + CD11b + granulocytes, including eosinophils, in the blood of CD45.1 recipients ( Supplemental Fig. 2B) ; thus, the results can be attributed to hematopoietic cells rather than lung tissue cells (such as endothelial cells, which are known to express CAR4; Ref. 20) . FACS analysis of BALF eosinophil CAR4 expression confirmed the bone marrow transfer efficiency (Fig. 6A) , whereas FACS enumeration revealed no difference in eosinophil levels between mice receiving Car4 +/+ and Car4 2/2 cells (Fig. 6B) . For direct evaluation of eosinophil trafficking, we applied a recently reported eosinophil adoptive transfer model (23) and found no migration difference between Car4 +/+ and Car4 2/2 adoptively transferred eosinophils following recipient allergen challenges. Likewise, direct allergen challenge of Car4
and Car4 2/2 mice (without bone marrow transplantation) revealed no difference in airway eosinophilia (Supplemental Fig. 2C ).
The robust CAR4 induction on eosinophils during asthma suggests roles in lung tissue inflammatory processes; however, CAR4 did not directly affect eosinophil lung migration. To further understand the function of eosinophil CAR4 in asthma, we examined the transcriptional change of the whole-lung tissue from Car4 +/+ and Car4 2/2 CD45.2 bone marrow recipient mice that had been subsequently allergen challenged. With asthma induction, we identified 37 genes differentially expressed in the lung of mice that were reconstituted with Car4 +/+ compared with Car4
hematopoietic cells. The clustered heat-map identified 30 upregulated genes and 7 downregulated genes ( Fig. 6C ; see Supplemental Table II for gene list) in Car4 +/+ recipients versus Car4 2/2 recipients (n = 4 mice per group). Gene ontology analysis (http://toppgene.cchmc.org) (24) identified several pulmonary epithelium-related pathways, including keratinization, epithelial differentiation, anion exchange, and epidermal development (the top 10 bio-processes listed in Fig. 6D ). The genes and their functional interactions are displayed in a proposed interactive network (Fig. 6E) .
Discussion
Recently, a key role of eosinophils in promoting asthma exacerbations has become increasingly recognized, as agents that attenuate eosinophils (e.g., humanized anti-IL-5) are showing promising effects in patients with eosinophilic asthma (6, 25) . Responsiveness to biological interventions in asthma, such as anti-IL-5 and anti-IgE, appear to be particularly effective in patients with elevated levels of eosinophils, which are primarily identified by levels of sputum eosinophils (26) . These findings, as well as decades of research correlating asthma severity with eosinophil levels and the release of eosinophilic granule constituents into the lung interstitium, highlight the importance of eosinophil activation in asthma. However, specific molecules associated with eosinophil activation have not been convincingly identified, even though these would have great potential value in stratifying patients for therapeutic interventions. We used genome-wide microarray analysis on sorted murine eosinophils to identify candidate markers of activated eosinophils. The aberrant and robust expression of CAR4 on lung eosinophils was quite surprising, with Car4 being among the most dysregulated transcripts. There have been no reports regarding hematopoietic expression of this CO 2 /bicarbonate catalyst gene other than in osteoclasts, which express CAR4 and CAR2 (27) . In osteoclasts, CAR2 and CAR4 expression has been speculated to create an acidic milieu. Notably, the human asthmatic airway is an acidic microenvironment (28); therefore, infiltrating leukocytes could potentially modulate the local pH if they expressed surface CAR. Although we did not observe a difference in cellular and intracellular buffering capacity (11, 12) in vitro, we did demonstrate the pH buffering capacity of eosinophils, consistent with prior findings (29) . CAR4 buffering is also accompanied by a readily detectable intracellular activity (30) . As a fine assessment of eosinophil CAR4 function, we also used the lactate-induced acidification assay, in which the subtle cellular change due to extracellular pH buffering is measured. Specifically, CAR4 buffering is mirrored by lactate-H + cotransport, which depends on CAR4 buffering and results in a reduction in pHi, a known function of CAR4 (21) . Despite the negative phenotype, these results do not rule out the possibility that eosinophil-expressed CAR4 contributes to acid balance in the lung in vivo. Of interest, CAR4 is expressed on the outer surface of the plasma membrane of IL-5-activated eosinophils, consistent with a function in trans rather than a role in cis. Nevertheless, CAR4
+ and CAR4 -eosinophils exhibited similar functional responses in terms of recruitment to the lung and eotaxin signaling.
On the basis of IL-5 inducing CAR4 in vitro and in vivo, we proposed that CAR4 is modulated by the Th2 cytokine IL-5 (4). It http://www.jimmunol.org/ is conceivable that the novel function of CAR4 in asthma pathogenesis is related to the eosinophil effector function following cellular activation. Notably, eosinophilia in the asthmatic lung is not sufficient to induce eosinophil CAR4 expression because overexpression of IL-13 does not upregulate CAR4 in the absence of pathogenic levels of IL-5. Recent research suggests that orally administrated CAR1 positively regulates regulatory T cells and negatively regulates Th17 cells, with a negative impact on inflammatory bowel disease pathogenesis (31); CAR2 and CAR4 are associated with pathogenesis of cystic fibrosis (32) and infectious diarrhea (13) ; and CAR9 may be associated with gastrointestinal malignancies (33) , suggesting a link between CARs and immune regulation. CAR4 is known to be expressed on alveolar capillary endothelium (20) , hindering precise phenotypic interpretation of the regular Car4 2/2 mice, as CAR4 is expressed on both hematopoietic and nonhematopoietic lung tissues. The bone marrow chimeric design overcomes this anatomical confounding factor in that a difference is solely attributable to CD45 + leukocytes. Therefore, the genes dysregulated within the resident lung tissue following bone marrow transfer are likely due to the robust CAR4 expression on infiltrating eosinophils, whereas the recipient's basal lung CAR4 expression may explain why Car4 did not appear on the significant gene list owing to dosage dilution and limited sensitivity. Accordingly, in the context of the induction of asthma and CAR4 expression, the gene ontology analysis of the lung tissue microarray data highlights a variety of potential functions for eosinophil CAR4, including the regulation of keratinization, differentiation of the epithelium, and bicarbonate and anion transport. A recent microarray study from human asthmatic sputum identified a series of 57 genes characterizing airway eosinophil activation (34) . Despite intriguing results and similar genome-wide approaches, this was not an eosinophil-specific approach, which may explain the absence of CAR4 on their screening list. In addition, the contribution from CAR4 expressed by noneosinophil leukocytes (such as macrophages) in our study cannot be entirely ruled out.
In summary, we have used a practical FACS/genome-wide screening-based discovery system to interrogate transcriptional changes of eosinophils during their recruitment to the asthmatic lung. The plasma membrane-associated metabolizing enzyme CAR4 was found to be aberrantly expressed on lung eosinophils after IL-5-induced activation in allergic airway inflammation. Although CAR4 does not directly regulate the intensity of eosinophilia, we have identified a series of lung transcripts that provide insight into the potential functions that eosinophil CAR4 may have in the context of allergic airway inflammation, namely, in the processes of airway epithelial cell differentiation, anion exchange, and keratinization. Collectively, this study highlights the significance of using a cell-specific, genome-wide screening model in the context of a disease model and identifies CAR4 as an eosinophil surface molecule tightly upregulated in IL-5-elicited eosinophilia.
